{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:59:15Z","timestamp":1768870755518,"version":"3.49.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Fr\u00fchdiagnostik der Alzheimer-Demenz (ADD) hat durch die Entdeckung der\n                    Blutbiomarker eine neue Bedeutung gewonnen. Blutbiomarker sind g\u00fcnstiger, k\u00f6nnen\n                    vollautomatisiert mit hoher Durchsatzf\u00e4higkeit gemessen werden, sind weniger\n                    invasiv und erm\u00f6glichen eine schnellere Information \u00fcber spezifische\n                    Demenzbiomarker als derzeitige in der klinischen Routine angewandte Verfahren\n                    wie die Amyloid-Positronen Emission Tomographie (PET) oder die Liquor\n                    Untersuchung \u00fcber pathologische Ver\u00e4nderungen der Alzheimer-Krankheit (AD) bei\n                    Patienten mit kognitiven Einschr\u00e4nkungen. Ziel dieser \u00dcbersicht ist die\n                    Darstellung des Mehrwerts blutbasierter Biomarker zur Fr\u00fchdiagnostik der ADD. Es\n                    werden einzelne Blutbiomarker hinsichtlich deren diagnostischer Sicherheit und\n                    pr\u00e4diktiver Wertigkeit f\u00fcr die Diagnose einer AD bei Vorstufen einer ADD von\n                    subjektiv kognitiver Beeintr\u00e4chtigung (SCD) bis hin zur leichten kognitiven\n                    Beeintr\u00e4chtigung (MCI) dargestellt. Zudem werden die revidierten Kriterien f\u00fcr\n                    die Diagnose und die Stadieneinteilung der AD diskutiert. Als spezifische\n                    Biomarker der Fr\u00fchdiagnostik einer AD werden Marker einer Tau-Pathologie wie ein\n                    phosphoryliertes Tau Protein 217 (p-tau217), ein phosphoryliertes Tau Protein\n                    181 (p-tau181), ein phosphoryliertes Tau Protein 231 (p-tau231), aber auch\n                    Amyloid-\u03b2 (A\u03b2) Marker wie die Ratio aus A\u03b21-42\/ 1-40 beschrieben. Dar\u00fcber hinaus\n                    werden neue vielversprechende Amyloid Peptidquotienten als wie die A\u03b2-3-42\/-3-40\n                    er\u00f6rtert, die mehr Einblicke in die Pathogenese der AD ergeben k\u00f6nnten, da diese\n                    N-terminal elongierten A\u03b2 Peptide \u00fcber einen biochemisch von\n                    Oligodendroglia-abh\u00e4ngigen Pfad (ADAMTS4=disintegrin and metalloproteinase with\n                    thrombospondin motifs 4) von dem Amyloid Vorl\u00e4ufer Protein gespalten werden, der\n                    aufgrund der Oligodendroglia-Beteiligung wichtig bei der AD-Pathophysiologie\n                    ist. Zudem werden neue vielversprechende zusammengesetzte Hybrid-Ratios\n                    erl\u00e4utert, die Vorteile in der Fr\u00fchdiagnostik der AD ergeben k\u00f6nnten wie der\n                        AT217-Begriff oder der AT181-Begriff, der A\u03b21-40 zu\n                    A\u03b21-42 ins Verh\u00e4ltnis setzt und mit p-tau217 beziehungsweise p-tau181\n                    multipliziert. Insgesamt liefert die \u00dcbersichtsarbeit somit einen \u00dcberblick \u00fcber\n                    das Potenzial von Blutbiomarkern bei der Fr\u00fchdiagnostik der ADD, die jedoch\n                    nicht alleine zur Fr\u00fchdiagnostik, sondern immer in der Zusammenschau mit anderen\n                    Untersuchungen wie dem Liquor evaluiert werden sollten.<\/jats:p>","DOI":"10.1055\/a-2698-5992","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T23:44:11Z","timestamp":1762472651000},"page":"446-452","source":"Crossref","is-referenced-by-count":1,"title":["Neues zur Blutbiomarker gest\u00fctzten Fr\u00fchdiagnostik der Vorstufen einer\n                    Alzheimer-Demenz"],"prefix":"10.1055","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-9594","authenticated-orcid":false,"given":"Niels","family":"Hansen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), G\u00f6ttingen,\n                    Germany"},{"name":"Biomedizinisches Institut (iBiMED), Universit\u00e4t von Aveiro, Aveiro,\n                    Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: a priority for European\n                    science and society","volume":"15","author":"B Winblad","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-beta Pathway in Alzheimer\u2019s Disease","volume":"26","author":"H Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s\n                    Association Workgroup","volume":"20","author":"C R Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"Contributors. NIA-AA Research Framework: Toward a biological definition of\n                    Alzheimer\u2019s disease","volume":"14","author":"C R Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14119","article-title":"DELCODE study group, SILCODE study group; Wagner M, Jessen F, Han Y, Kuhn E.\n                    Amyloid and SCD jointly predict cognitive decline across Chinese and German\n                    cohorts","author":"K Shao","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","article-title":"Plasma Phosphorylated Tau 217 and A\u03b242\/40 to Predict Early Brain A\u03b2 Accumulation\n                    in People Without Cognitive Impairment","volume":"81","author":"S Janelidze","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.02.24309629","article-title":"A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217\n                    Biomarker Tests","author":"N Warmenhoven","year":"2024","journal-title":"medRxiv [Preprint]"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e2413855","DOI":"10.1001\/jama.2024.13855","article-title":"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary\n                    Care","author":"S Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1002\/alz.13909","article-title":"Plasma amyloid beta X-42\/X-40 ratio and cognitive decline in suspected early and\n                    preclinical Alzheimer\u2019s disease","volume":"20","author":"J Vogelgsang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology \u2013\n                    recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"S E Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.14283\/jpad.2022.17","article-title":"Sensitivity of the Preclinical Alzheimer\u2019s Cognitive Composite (PACC), PACC5,\n                    and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status\n                    in Preclinical Alzheimer\u2019s Disease -Atabecestat Phase 2b\/3 EARLY Clinical\n                    Trial","volume":"9","author":"K V Papp","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13195-022-01104-6","article-title":"Plasma amyloid-beta oligomer is related to subjective cognitive decline and\n                    brain amyloid status","volume":"14","author":"K Y Kim","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00109-009-0568-7","article-title":"Beta-amyloid oligomers and cellular prion protein in Alzheimer\u2019s disease","volume":"88","author":"E C Gunther","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13195-023-01273-y","article-title":"CoSCo study group. Impacts of baseline biomarkers on cognitive trajectories in\n                    subjective cognitive decline: the CoSCo prospective cohort study","volume":"15","author":"Y J Hong","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"A Nakamura","year":"2018","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00401-018-1929-5","article-title":"The metalloprotease ADAMTS4 generates N-truncated A\u03b24-x species and marks\n                    oligodendrocytes as a source of amyloidogenic peptides in Alzheimer\u2019s\n                    disease","volume":"137","author":"S Walter","year":"2019","journal-title":"Acta Neuropathol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e12991","DOI":"10.1111\/nan.12991","article-title":"Amino-terminally elongated A\u03b2 peptides are generated by the secreted\n                    metalloprotease ADAMTS4 and deposit in a subset of Alzheimer\u2019s disease\n                    brains","volume":"50","author":"O Wirths","year":"2024","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1523\/JNEUROSCI.2146-22.2023","article-title":"ADAMTS4 Enhances Oligodendrocyte Differentiation and Remyelination by Cleaving\n                    NG2 Proteoglycan and Attenuating PDGFR\u03b1 Signaling","volume":"43","author":"C Jiang","year":"2023","journal-title":"J Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-023-06120-6","article-title":"Myelin dysfunction drives amyloid-\u03b2 deposition in models of Alzheimer\u2019s\n                    disease","volume":"618","author":"C Depp","year":"2023","journal-title":"Nature."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41593-024-01730-3","article-title":"Oligodendrocytes produce amyloid-\u03b2 and contribute to plaque formation alongside\n                    neurons in Alzheimer\u2019s disease model mice","volume":"27","author":"A O Sasmita","year":"2024","journal-title":"Nat Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","article-title":"A novel ultrasensitive assay for plasma p-tau217: Performance in individuals\n                    with subjective cognitive decline and early Alzheimer\u2019s disease","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14100","article-title":"Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a\n                    non-demented Alzheimer\u2019s risk-enhanced sample","author":"L Du","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer\n                    Disease Pathology","volume":"81","author":"N J Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"11307","DOI":"10.1038\/s41598-024-61655-6","article-title":"Future perspective and clinical applicability of the combined use of plasma\n                    phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive\n                    Decline and Mild Cognitive Impairment","volume":"14","author":"G Giacomucci","year":"2024","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"105345","DOI":"10.1016\/j.ebiom.2024.105345","article-title":"Clinical value of plasma pTau181 to predict Alzheimer\u2019s disease pathology in a\n                    large real-world cohort of a memory clinic","volume":"108","author":"A Cano","year":"2024","journal-title":"EBioMedicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s40520-022-02148-2","article-title":"Alzheimer\u2019s disease Neuroimaging Initiative (ADNI). Plasma p-tau181 associated\n                    with structural changes in mild cognitive impairment","volume":"34","author":"F Nabizadeh","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01751-2","article-title":"Assessment of immunoprecipitation with subsequent immunoassays for the\n                    blood-based diagnosis of Alzheimer\u2019s disease","author":"B Morgado","year":"2024","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in\n                    preclinical Alzheimer\u2019s disease","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14245","article-title":"Shanghai Memory Study (SMS). Pilot implementation of the revised criteria for\n                    staging of Alzheimer\u2019s disease by the Alzheimer\u2019s Association Workgroup in a\n                    tertiary memory clinic","author":"J Lu","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s\n                    disease","author":"M Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longev"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2698-5992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T23:44:14Z","timestamp":1762472654000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2698-5992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2698-5992","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}